A systems perspective of ras signaling in cancer

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1510-1513

  Stites, Edward C ^a   Ravichandran, Kodi S ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GUANOSINE TRIPHOSPHATASE; PROTEIN INHIBITOR; RAS PROTEIN;

CANCER CELL; DISEASE COURSE; DRUG DESIGN; DRUG PROTEIN BINDING; ENZYME ACTIVITY; MOLECULAR MODEL; NEOPLASM; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

COMPUTATIONAL BIOLOGY; GENES, RAS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 63449108226     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2753     Document Type: Review

References (58)

1. Anderson AR, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer 2008;8:227-34.
2. Nowak MA, Michor F, Komarova NL, IwasaY Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A 2004;101:10635-8.
3. Spencer SL, Gerety RA, Pienta KJ, Forrest S. Modeling somatic evolution in tumorigenesis. PLoS Comput Biol 2006;2:e108.
4. Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006;127:905-15.
5. Michor F, HughesTP, IwasaY, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70.
6. Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK. Physicochemical modelling of cell signalling pathways. Nat Cell Biol 2006;8:1195-203.
7. Wiley HS, Shvartsman SY, Lauffenburger DA. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol 2003; 13:43-50.
8. Kholodenko BN, Demin OV, Moehren G, Hoek JB. Quantification of short term signaling by the epidermal growth factor receptor. J Biol Chem 1999;274: 30169-81.
9. Blinov ML,Faeder JR, GoldsteinB,HlavacekWS.A networkmodel of early events in epidermal growth factor receptor signaling that accounts for combinatorial complexity. Biosystems 2006;83:136-51.
10. Markevich NI, Moehren G, Demin OV, et al. Signal processing at the Ras circuit: What shapes Rasactivation patterns? Syst Biol (Stevenage.) 2004;1:104-13.
11. Tian T, Harding A, Inder K, Plowman S, Parton RG, HancockJF. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nat Cell Biol 2007;9:905-14.
12. Stites EC, Trampont PC, Ma Z, Ravichandran KS. Networkanalysis of oncogenic Ras activation in cancer. Science 2007;318:463-7.
13. Huang CY, Ferrell JE, Jr. Ultrasensitivity in the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1996;93:10078-83.
14. Fujioka A, Terai K, Itoh RE, et al. Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes. J Biol Chem 2006;281:8917-26.
15. Bhalla US, Ram PT, Iyengar R. MAP kinase phos-phatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002;297: 1018-23.
16. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 2002;20:370-5.
17. Hatakeyama M, Kimura S, NakaT, et al. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. Biochem J 2003;373:451 -63.
18. Sasagawa S, Ozaki Y, Fujita K, Kuroda S. Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat Cell Biol 2005;7:365-73.
19. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-31.
20. Milburn MV, Tong L, deVos AM, et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 1990;247:939-45.
21. Herrmann C, Martin GA, Wittinghofer A. Quantitative analysis of the complex between p21ras and the Ras-binding domain of the human Raf-1 protein kinase. J Biol Chem 1995;270:2901 -5.
22. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541 -55.
23. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-7.
24. James GL, GoldsteinJL, Brown MS, et al. Benzodiazepine peptidomimetics: potentinhibitors of Rasfarnesy-lation in animal cells. Science1993;260:1937-42.
25. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-7.
26. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002;1602:23-45.
27. Lenzen C, Cool RH, Prinz H, Kuhlmann J, Wittinghofer A. Kinetic analysis by fluorescence of the interaction between Ras and the catalytic domain of the guanine nucleotide exchange factor Cdc25Mm. Biochemistry 1998;37:7420-30.
28. Ahmadian MR, Hoffmann U, Goody RS, Wittinghofer A. Individual rate constants for the interaction of Ras proteins with GTPase-activating proteins determined by fluorescence spectroscopy. Biochemistry 1997;36:4535-41.
29. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007;129:865-77.
30. Rudolph MG, Linnemann T, Grunewald P, WittinghoferA,Vetter IR, Herrmann C. Thermodynamics of Ras/effector and Cdc42/effector interactions probed by isothermal titration calorimetry. J Biol Chem 2001;276:23914-21.
31. ClarkGJ, Drugan JK, Terrell RS, et al. Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPaseactivating protein NF1inhibit Rasfunction. Proc Natl Acad Sci U S A1996;93:1577-81.
32. Trahey M, McCormickF. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987;238:542-5.
33. Chuang E, Barnard D, Hettich L, Zhang XF, Avruch J, Marshall MS. Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Biol 1994;14:5318-25.
34. Wolf J, Dronov S,Tobin F, Goryanin I. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations. FEBS J 2007;274: 5505-17.
35. Breitling R, Hoeller D. Current challenges in quantitative modeling of epidermal growth factor signaling. FEBS Lett 2005;579:6289-94.
36. Nolan GP. What's wrong with drug screening today. Nat Chem Biol 2007;3:187-91.
37. Somogyi R, Greller LD. The dynamics of molecular networks: applications to therapeutic discovery. Drug Discov Today 2001;6:1267-77.
38. Davidov E, Holland J, Marple E, Naylor S. Advancing drug discovery through systems biology. Drug Discov Today 2003;8:175-83.
39. Ahmadian MR, ZorT, Vogt D, et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci U S A1999;96:7065-70.
40. Hendriks BS, Hua F, Chabot JR. Analysis of mechanistic pathway models in drug discovery: p38 pathway. Biotechnol Prog 2008;24:96-109.
41. Fitzgerald JB, Schoeber lB, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-66.
42. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11 -22.
43. Nur-E-KamalMS,Varga M,Maruta H. The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype. J Biol Chem 1993;268:22331 -7.
44. Nakafuku M, Nagamine M, Ohtoshi A, Tanaka K, Toh-e A, KaziroY. Suppression of oncogenic Ras by mutant neurofibromatosis type 1 genes with single amino acid substitutions. Proc Natl Acad Sci USA 1993;90:6706-10.
45. Mori S, SatohT, Koide H, Nakafuku M,Villafranca E, Kaziro Y. Inhibition of Ras/Raf interaction by anti-oncogenic mutants of neurofibromin, the neurofibromatosis type 1 (NF1) gene product, in cell-free systems. J Biol Chem 1995;270:28834-8.
46. Tanaka T, Williams RL, RabbittsTH. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J 2007;26:3250-9.
47. Cochet O, Kenigsberg M, Delumeau I, et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res 1998; 58:1170-6.
48. Ganguly AK, Wang YS, PramanikBN, et al. Interaction of a novel GDP exchange inhibitor with the Ras protein. Biochemistry 1998;37:15631 -7.
49. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003;3:459-65.
50. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006;6:117-29.
51. Ikediobi ON. Somatic pharmacogenomics in cancer. Pharmacogenomics J 2008;8:305-14.
52. PaoW,MillerV, Zakowski M,et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
53. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
54. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34.
55. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
56. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
57. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
58. Hlavacek WS, Faeder JR, Blinov ML, Perelson AS, Goldstein B. The complexity of complexes in signal transduction. Biotechnol Bioeng 2003;84:783-94.